Jaguar Health Inc JAGX.OQ JAGX.O is expected to show a rise in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
The San Francisco California-based company is expected to report a 20.0% increase in revenue to $3.265 million from $2.72 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Jaguar Health Inc is for a loss of $7.13 per share.
The one available analyst rating on the shares is "strong buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Jaguar Health Inc is $16.00, about 86.9% above its last closing price of $2.10
This summary was machine generated August 8 at 17:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)